Smartleaf Asset Management LLC Has $47,000 Stock Holdings in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)

Smartleaf Asset Management LLC lifted its position in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) by 219.1% in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 1,267 shares of the specialty pharmaceutical company’s stock after buying an additional 870 shares during the quarter. Smartleaf Asset Management LLC’s holdings in Supernus Pharmaceuticals were worth $47,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors have also modified their holdings of SUPN. Newbridge Financial Services Group Inc. bought a new stake in shares of Supernus Pharmaceuticals during the 4th quarter worth about $72,000. Venturi Wealth Management LLC bought a new position in Supernus Pharmaceuticals in the 4th quarter worth approximately $92,000. KBC Group NV lifted its holdings in shares of Supernus Pharmaceuticals by 53.1% during the fourth quarter. KBC Group NV now owns 2,679 shares of the specialty pharmaceutical company’s stock worth $97,000 after buying an additional 929 shares during the last quarter. Janney Montgomery Scott LLC acquired a new stake in shares of Supernus Pharmaceuticals in the fourth quarter worth $211,000. Finally, Quest Partners LLC bought a new position in Supernus Pharmaceuticals during the third quarter worth $241,000.

Insider Activity

In other Supernus Pharmaceuticals news, VP Padmanabh P. Bhatt sold 9,477 shares of the stock in a transaction on Tuesday, February 4th. The stock was sold at an average price of $39.70, for a total transaction of $376,236.90. Following the completion of the transaction, the vice president now directly owns 10,149 shares in the company, valued at $402,915.30. This represents a 48.29 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, SVP Jonathan Rubin sold 927 shares of the business’s stock in a transaction on Friday, February 21st. The shares were sold at an average price of $39.15, for a total transaction of $36,292.05. Following the completion of the sale, the senior vice president now owns 7,853 shares in the company, valued at $307,444.95. This represents a 10.56 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders sold 11,104 shares of company stock worth $440,263. 9.30% of the stock is currently owned by corporate insiders.

Analyst Upgrades and Downgrades

A number of brokerages have weighed in on SUPN. StockNews.com downgraded shares of Supernus Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Saturday. Cantor Fitzgerald reiterated a “neutral” rating and issued a $36.00 target price on shares of Supernus Pharmaceuticals in a research note on Wednesday, February 26th.

Supernus Pharmaceuticals Trading Down 2.5 %

Shares of NASDAQ SUPN opened at $32.02 on Wednesday. Supernus Pharmaceuticals, Inc. has a one year low of $25.53 and a one year high of $40.28. The business has a fifty day simple moving average of $36.54 and a 200 day simple moving average of $35.25. The firm has a market capitalization of $1.79 billion, a price-to-earnings ratio of 29.93 and a beta of 0.83.

About Supernus Pharmaceuticals

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.